• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Rajavelu Esther was granted 185,000 shares, increasing direct ownership by 26% to 909,720 units (SEC Form 4)

    5/6/25 8:01:37 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rajavelu Esther

    (Last) (First) (Middle)
    C/O SPERO THERAPEUTICS, INC.
    675 MASSACHUSETTS AVENUE, 14TH FLOOR

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Spero Therapeutics, Inc. [ SPRO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/02/2025 A 185,000(1) A $0 909,720 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on May 2, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
    Remarks:
    Chief Executive Officer, Chief Financial Officer and Chief Business Officer
    /s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SPRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRO

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SPRO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Spero Therapeutics Inc.

      DEFA14A - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:29:35 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Spero Therapeutics Inc.

      DEF 14A - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:15:59 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Spero Therapeutics Inc.

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:02:27 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Rajavelu Esther was granted 185,000 shares, increasing direct ownership by 26% to 909,720 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      5/6/25 8:01:37 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Keutzer Timothy was granted 266,139 shares and sold $44,099 worth of shares (56,537 units at $0.78), increasing direct ownership by 39% to 741,439 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 9:04:51 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & CBO Rajavelu Esther sold $16,137 worth of shares (20,689 units at $0.78) and was granted 366,139 shares, increasing direct ownership by 91% to 724,720 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 8:52:39 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

      CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

      11/1/23 8:05:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/24 5:37:55 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/24 4:25:21 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/23 11:47:54 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Financials

    Live finance-specific insights

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

      CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

      3/18/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spero Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

      12/20/24 7:51:16 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

      9/23/22 7:52:34 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

      10/1/21 6:10:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care